ADC Therapeutics Presents LOTIS-7 Clinical Trial Insights
ADC Therapeutics SA (NYSE: ADCT), a pioneering force in antibody drug conjugates (ADCs), is set to present compelling data from its LOTIS-7 Phase 1b clinical trial concerning the combination of ZYNLONTA (loncastuximab tesirine-lpyl) and glofitamab (COLUMVI). This study focuses on patients experiencing relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The results indicate an impressive overall response rate (ORR) of 95.5% and a complete response (CR) rate of 90.9% among 22 evaluable patients.
Key Findings from the LOTIS-7 Trial
The trial showcases encouraging safety and tolerability profiles consistent with the established characteristics of both ZYNLONTA and glofitamab. Data will be presented at the European Hematology Association (EHA) Congress and the International Conference on Malignant Lymphoma (ICML).
Details of Upcoming Presentations
The presentation will take place during the following sessions:
EHA2025 Poster Presentation
Title: Initial Results from LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory DLBCL
Session Date: Saturday, June 14 at 12:30 p.m. ET
Location: Poster Hall, Allianz MiCo, Milano Convention Centre
ICML Oral Presentation
Title: Initial Results from LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory DLBCL
Session Date: Friday, June 20 at 8:00 a.m. ET
Location: Room A, Lugano Convention Centre, Palazzo dei Congressi
Importance of the LOTIS-7 Data
Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics, expressed enthusiasm about the upcoming presentations, highlighting how the robust efficacy and manageable safety of the combination of ZYNLONTA and glofitamab have the potential to transform treatment approaches for patients facing aggressive lymphomas. The abstract reveals key data including the overall response rate (ORR) and complete response rate (CR) were 95.5% (21/22) and 90.9% (20/22) respectively.
Future Directions of ADC Therapeutics
ADC Therapeutics continues to innovate in the realm of antibody drug conjugates, aiming to enhance the treatment landscape for hematologic malignancies. The company is not only focusing on advancing ZYNLONTA but also exploring its use in combination with various agents across different treatment lines.
About ZYNLONTA
ZYNLONTA is designed as a CD19-directed ADC targeting B-cell malignancies. Following binding to CD19-expressing cells, ZYNLONTA releases a potent modulus that hinders DNA repair processes, resulting in effective tumor cell death. The FDA and EMA have granted approvals for ZYNLONTA to treat adult patients with relapsed or refractory DLBCL, marking a significant advancement in addressing challenging cancer cases.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is headquarted in Lausanne, Switzerland, and actively pursues advancements in antibody drug conjugates. The ongoing commitment to innovation places ADC Therapeutics at the forefront of therapeutic possibilities for patients with challenging hemtalogical conditions. The company is dedicated to enhancing patient outcomes through clinical excellence and groundbreaking research.
Frequently Asked Questions
1. What is the LOTIS-7 trial?
The LOTIS-7 trial is a Phase 1b clinical study evaluating the effectiveness of ZYNLONTA in combination with glofitamab for treating patients with relapsed or refractory DLBCL.
2. What were the main findings of the LOTIS-7 trial?
The trial demonstrated an impressive ORR of 95.5% and a CR rate of 90.9% among evaluable patients, indicating strong potential efficacy.
3. When will the results be presented?
Results will be presented at the EHA Congress on June 14 and ICML on June 20, highlighting the latest findings from the study.
4. What is ZYNLONTA?
ZYNLONTA is a CD19-directed antibody drug conjugate used for treating adult patients with relapsed or refractory DLBCL, showing promise in enhancing patient outcomes.
5. What is ADC Therapeutics' mission?
ADC Therapeutics aims to transform cancer treatment through advanced antibody drug conjugate technologies, focusing on improving therapies for hematologic malignancies and solid tumors.
